Your browser is no longer supported. Please, upgrade your browser.
ICPT Intercept Pharmaceuticals, Inc. monthly Stock Chart
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.08 Insider Own2.40% Shs Outstand24.20M Perf Week5.60%
Market Cap4.59B Forward P/E- EPS next Y-11.92 Insider Trans-58.20% Shs Float17.22M Perf Month-28.07%
Income-157.90M PEG- EPS next Q-2.75 Inst Own75.50% Short Float13.89% Perf Quarter-24.60%
Sales2.80M P/S1640.07 EPS this Y-262.50% Inst Trans2.52% Short Ratio6.72 Perf Half Y-23.29%
Book/sh30.10 P/B6.30 EPS next Y-15.40% ROA-36.80% Target Price387.56 Perf Year-34.50%
Cash/sh30.26 P/C6.27 EPS next 5Y7.00% ROE-39.20% 52W Range128.50 - 314.88 Perf YTD21.64%
Dividend- P/FCF- EPS past 5Y0.00% ROI-49.00% 52W High-41.65% Beta-
Dividend %- Quick Ratio31.10 Sales past 5Y- Gross Margin- 52W Low42.97% ATR12.97
Employees136 Current Ratio31.10 Sales Q/Q0.00% Oper. Margin- RSI (14)29.96 Volatility6.78% 6.55%
OptionableYes Debt/Eq0.00 EPS Q/Q-231.80% Profit Margin- Rel Volume1.10 Prev Close189.76
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume355.80K Price183.72
Recom2.10 SMA20-13.80% SMA50-23.55% SMA200-18.53% Volume266,131 Change-3.18%
Aug-13-15Initiated Morgan Stanley Underweight $165
May-21-15Initiated Barclays Overweight $425
May-19-15Downgrade BofA/Merrill Buy → Neutral
Apr-17-15Initiated UBS Buy $465
Mar-17-15Initiated MLV & Co Hold $273
Jan-28-15Reiterated Oppenheimer Outperform $499 → $375
Dec-04-14Initiated Robert W. Baird Outperform $258
Dec-03-14Reiterated FBR Capital Underperform $125 → $99
Nov-10-14Reiterated FBR Capital Underperform $172 → $125
Aug-15-14Initiated FBR Capital Underperform $172
Aug-12-14Reiterated RBC Capital Mkts Outperform $425 → $500
Jul-01-14Initiated RBC Capital Mkts Outperform $425
May-15-14Initiated Summer Street Research Buy $650
May-08-14Reiterated Oppenheimer Outperform $525 → $499
Mar-18-14Reiterated Needham Buy $320 → $500
Mar-14-14Reiterated Oppenheimer Outperform $360 → $525
Jan-10-14Reiterated Oppenheimer Outperform $94 → $360
Jan-10-14Reiterated Needham Buy $55 → $320
Oct-01-13Reiterated Oppenheimer Outperform $64 → $94
Aug-13-13Reiterated Needham Buy $40 → $55
Sep-01-15 06:51AM  Intercept Pharma Could Be Bought for $493 a Share at Barrons.com
Aug-31-15 07:05AM  FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis GlobeNewswire
Aug-20-15 09:32PM  4 Reasons Intercept Pharmaceuticals Should Be on Your Radar at Investopedia -7.10%
Aug-15-15 01:04PM  INTERCEPT PHARMACEUTICALS INC Financials
Aug-13-15 12:11PM  Intercept Pharma Dips As Analyst Doubts NASH Market at Investor's Business Daily -7.89%
06:19AM  Coverage initiated on Intercept Pharma by Morgan Stanley
Aug-07-15 07:27AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-06-15 02:31PM  Intercept Pharmaceuticals' Q2 Loss Wider than Expected - Analyst Blog -7.75%
Aug-05-15 11:55PM  Edited Transcript of ICPT earnings conference call or presentation 5-Aug-15 8:30pm GMT
06:55PM  Intercept reports 2Q loss
04:17PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
04:05PM  Intercept Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Business Update GlobeNewswire
07:07AM  Q2 2015 Intercept Pharmaceuticals Inc Earnings Release - After Market Close
Aug-04-15 01:15PM  Intercept Pharmaceuticals (ICPT): Q2 Earnings Preview - Analyst Blog
Jul-29-15 04:05PM  Intercept to Report Second Quarter 2015 Financial Results on August 5 and Present at Upcoming Conferences GlobeNewswire
Jul-21-15 04:05PM  Intercept Pharmaceuticals Appoints Richard Kim as Senior Vice President, Commercial Head of U.S. GlobeNewswire
Jul-09-15 05:26PM  Gilead's next target?
Jul-07-15 09:45AM  Intercept Pharmaceuticals Makes a Breakthrough at Investopedia
Jul-02-15 05:56PM  DALCOMP NEGOTIATED CALENDAR Reuters
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Press Releases
Jul-01-15 11:29AM  Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Analyst Blog
Jun-30-15 02:35PM  Intercept Pharmaceuticals Files for OCA in U.S. and Europe - Analyst Blog
06:02AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Jun-29-15 04:05PM  Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis GlobeNewswire -5.99%
Jun-22-15 06:00AM  Intercept Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, M.D., Ph.D. as Senior Vice President of Medical Affairs GlobeNewswire
Jun-17-15 10:30PM  Edited Transcript of ICPT earnings conference call or presentation 11-May-15 1:45pm GMT
08:20AM  LLTP Shares Attractive On Rolling NDA Submission - 300 Percent in Potential Upside
Jun-11-15 01:36PM  Edited Transcript of ICPT presentation 10-Jun-15 10:20pm GMT
May-26-15 08:30AM  4 Big Biotech Companies to Sell Now at TheStreet
May-23-15 08:10AM  What You May Have Missed in Biotech: Eye Drug Fails, Ear Drug Flops, and Herpes Drug Succeeds at Forbes
May-22-15 09:02PM  Will This Drug Beat Gilead to Market in NASH? at Investopedia
May-21-15 02:19PM  Biotech: Don't Bet Against Small Caps Just Yet at Barrons.com
10:27AM  Two Picks Boosted by Intercept NASH Trial at Barrons.com
09:00AM  4 SMID-Cap Biotechs Barclays Just Confessed It Loves
May-20-15 03:25PM  Intercept Pharmaceuticals Reveals Phase III OCA Study Plan - Analyst Blog
08:45AM  Intercept Pharmaceuticals (ICPT) in Focus: Stock Tanks 16.1% - Tale of the Tape
08:27AM  Intercept Pharmaceuticals Downgraded
May-19-15 05:36PM  Stock Pops & Drops: GPRO, ICPT, RIG & RCL -16.08%
05:27PM  Intercept's NASH Trial Design Irks Investors at Investor's Business Daily
04:15PM  Intercept Drops as Liver Trial Will Be Larger Than Expected at Bloomberg
02:00PM  Is This the End of the Growth Phase for Intercept? at 24/7 Wall St.
11:02AM  Bluebird Bio, Intercept Pharma Reach Accords on Pivotal Trial Designs at TheStreet
06:00AM  Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH GlobeNewswire
May-13-15 10:56AM  Intercept Pharmaceuticals Breaks Out
May-11-15 04:26PM  Intercept Pharma (ICPT) Stock Rose Following Earnings Release at TheStreet
08:35AM  Intercept Pharmaceuticals' (ICPT) Loss Widens in Q1 - Tale of the Tape
08:31AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
07:07AM  Q1 2015 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open
06:42AM  Intercept reports 1Q loss
06:01AM  Intercept Pharmaceuticals Announces First Quarter 2015 Financial Results GlobeNewswire
May-07-15 05:23PM  Will Intercept Pharmaceuticals (ICPT) Miss on Q1 Earnings? - Analyst Blog
May-04-15 04:24PM  Intercept to Report First Quarter 2015 Financial Results on May 11 and Present at Upcoming Conferences at noodls
04:05PM  Intercept to Report First Quarter 2015 Financial Results on May 11 and Present at Upcoming Conferences GlobeNewswire
Apr-30-15 09:26PM  Gilead CEO: We are taking suggestions on companies to buy at Fortune -5.22%
Apr-24-15 05:24PM  Intercept Pharmaceuticals Releases Data on Lead Drug - Analyst Blog
09:12AM  Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug at TheStreet
Apr-23-15 03:53AM  Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients at noodls
03:35AM  Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients GlobeNewswire
Apr-18-15 11:20AM  4 Biotech and Pharma Stocks Projected to Rise 50% to 100% at 24/7 Wall St.
Apr-17-15 04:28PM  It was a day to forget on Wall Street...
02:33PM  Street Talk: ICPT under the radar
Apr-13-15 06:37AM  Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015 at noodls
06:01AM  Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015 GlobeNewswire
Apr-10-15 01:10PM  Biotech Investors: Nomura Says To Watch These Dates
Apr-08-15 02:51PM  Options Pro Says Intercept Shares Will Go 'Much Higher' Through The End Of The Year
Apr-07-15 07:41PM  Regulus Soars As AstraZeneca Grabs NASH Drug Rights at Investor's Business Daily
Apr-06-15 04:22PM  Intercept Pharmaceuticals Announces Completion of Public Offering at noodls
04:10PM  Intercept Pharmaceuticals Announces Completion of Public Offering GlobeNewswire
Apr-04-15 09:15AM  Massive Biotech Stock Sale Highlights Insider Selling Report at 24/7 Wall St.
Apr-02-15 05:14PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events
Mar-31-15 05:45PM  Stock Pops & Drops: DHI, ICPT, PCLN & DANG
12:41PM  Esperion Therapeutics Inc (ESPR), Intercept Pharmaceuticals Inc (ICPT): Visium and OrbiMeds Recent Activity in Biotech at Insider Monkey
09:23AM  Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock at noodls
09:14AM  Intercept Prices 1.2M Shares, Proceeds To Be ~$338.4M
09:13AM  Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
08:51AM  Genfit's French Fans Fume Following Failure of Fatty Liver Drug at TheStreet
07:51AM  Early movers: MRH, JCI, DHI, PHG, TEVA, CVC & more at CNBC
06:48AM  Intercept Pharmaceuticals Announces Proposed Offering of Common Stock at noodls
06:24AM  Intercept Pharmaceuticals Announces Proposed Offering of Common Stock GlobeNewswire
Mar-28-15 09:10AM  Insiders Join the Selling Party as Markets Post Steep Drop at 24/7 Wall St.
Mar-27-15 03:30PM  Genfit sinks 31%, but CEO defends liver drug results at CNBC
02:20PM  Drug trial setbacks
01:06PM  Genfit's Loss Is Gain For Intercept Pharmaceuticals
09:40AM  Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study at TheStreet
Mar-26-15 06:07PM  Nasdaq stocks posting largest percentage increases AP +8.46%
02:53PM  GenFit NASH Data Drives Up Rival Intercept at Investor's Business Daily
12:02PM  Healthcare Hedge Fund Orbimeds Top Picks and New Move at Insider Monkey
Mar-24-15 07:43AM  Why Intercept Might Be A Better Bet Than Biogen Right Now
Mar-20-15 09:28AM  What Were Trading
08:59AM  Stock Futures Up, Dollar Mixed; Nasdaq Zeros In On Fresh High at Investor's Business Daily
06:28AM  Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH at noodls
05:58AM  Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH GlobeNewswire
Mar-18-15 04:10PM  Is Intercept The Next Biotech To Break Out?
Mar-16-15 07:00PM  Lightning Round: The downgrade was wrong on this at CNBC
02:57PM  Intercept Pharmaceuticals Revisits $300 For The First Time In 7 Months
Mar-13-15 01:19PM  Biotech bull case: MNK & ICPT
Mar-11-15 09:58AM  Genfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know. at TheStreet +6.14%
Mar-09-15 03:32PM  Intercept Pharmaceuticals Announces 2014 Financial Results at noodls
02:34PM  Three Reasons to Fear Biotech Stocks Right Now at Barrons.com
Mar-02-15 10:48AM  Intercept Pharma (ICPT) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid (OCA), a bile acid analog that completed Phase III clinical trial for the treatment of primary biliary cirrhosis; is in Phase III clinical trial for the treatment of nonalcoholic steatohepatitis; is in Phase 2 clinical trial for primary sclerosing cholangitis; and is in Phase I clinical trial for the treatment of biliary atresia. The company's product candidates in preclinical stage include INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of fibrosis; and INT-777, an orally administered TGR5 agonist used in treating type 2 diabetes. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILLIAMS NICOLEDirectorAug 20Option Exercise9.829749,5671,936Aug 24 09:00 PM
WILLIAMS NICOLEDirectorAug 20Sale206.85974201,472962Aug 24 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 17Option Exercise8.673,50030,33322,505Aug 19 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 17Sale209.374,272894,42918,233Aug 19 09:00 PM
VEITINGER KLAUS R DRDirectorAug 03Option Exercise21.5050010,7502,666Aug 05 09:00 PM
VEITINGER KLAUS R DRDirectorAug 03Sale261.17500130,5852,166Aug 05 09:00 PM
McMinn RachelChief Strategy OfficerJul 31Sale262.0912733,2864,293Aug 04 09:02 PM
Fundaro PaoloDirectorJul 24Sale285.00582165,8708,221Jul 24 09:12 PM
WILLIAMS NICOLEDirectorJul 20Option Exercise9.829739,5571,935Jul 22 09:00 PM
WILLIAMS NICOLEDirectorJul 20Sale279.01973271,477962Jul 22 09:00 PM
Pruzanski MarkCEO & PresidentJul 10Option Exercise8.6712,500108,334519,514Jul 14 09:00 PM
Pruzanski MarkCEO & PresidentJul 10Sale250.0012,5003,125,000507,014Jul 14 09:00 PM
Adorini LucianoChief Scientific OfficerJul 06Option Exercise21.294,06786,58114,776Jul 08 09:00 PM
Adorini LucianoChief Scientific OfficerJul 06Sale579.934,0672,358,59110,709Jul 08 09:00 PM
Pruzanski MarkCEO & PresidentJul 02Sale236.2615837,328507,014Jul 07 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 02Sale236.29851201,08319,005Jul 07 09:00 PM
Duncan Barbara GayleChief Financial OfficerJul 02Sale236.265312,52218,768Jul 07 09:00 PM
Duncan Barbara GayleChief Financial OfficerJul 01Option Exercise8.671,0008,66718,523Jul 06 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Option Exercise8.673,50030,33322,014Jul 06 09:00 PM
Duncan Barbara GayleChief Financial OfficerJul 01Sale242.101,000242,10017,523Jul 06 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Sale238.663,781902,37818,233Jul 06 09:00 PM
WILLIAMS NICOLEDirectorJun 22Option Exercise9.829749,5671,936Jun 24 09:00 PM
WILLIAMS NICOLEDirectorJun 22Sale265.14974258,246962Jun 24 09:00 PM
VEITINGER KLAUS R DRDirectorJun 10Option Exercise21.503918,4072,557Jun 12 09:00 PM
VEITINGER KLAUS R DRDirectorJun 10Sale238.2139193,1402,166Jun 12 09:00 PM
Adorini LucianoChief Scientific OfficerJun 08Option Exercise8.674,00034,66714,060Jun 10 09:00 PM
Adorini LucianoChief Scientific OfficerJun 08Sale248.404,000993,59810,060Jun 10 09:00 PM
Pruzanski MarkCEO & PresidentJun 03Option Exercise17.766,561116,550502,304Jun 05 09:00 PM
WILLIAMS NICOLEDirectorMay 20Option Exercise9.829739,5571,935May 22 09:00 PM
WILLIAMS NICOLEDirectorMay 20Sale260.20973253,175962May 22 09:00 PM
AKKARAJU SRINIVASDirectorMay 19Option Exercise21.501,00021,5008,642May 22 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMay 15Option Exercise8.673,50030,33322,793May 19 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentMay 15Sale306.904,2791,313,24418,514May 19 09:01 PM
Pruzanski MarkCEO & PresidentMay 14Option Exercise8.675,00043,334500,743May 18 09:00 PM
Pruzanski MarkCEO & PresidentMay 14Sale300.005,0001,500,000495,743May 18 09:00 PM
VEITINGER KLAUS R DRDirectorMay 11Option Exercise21.503918,4072,557May 13 09:00 PM
VEITINGER KLAUS R DRDirectorMay 11Sale279.07391109,1172,166May 13 09:00 PM
Adorini LucianoChief Scientific OfficerMay 06Option Exercise8.674,00034,66714,060May 08 09:00 PM
Adorini LucianoChief Scientific OfficerMay 06Sale259.974,0001,039,86310,060May 08 09:00 PM
Pruzanski MarkCEO & PresidentMay 01Option Exercise8.6712,500108,334508,243May 05 09:00 PM
Pruzanski MarkCEO & PresidentMay 01Sale253.5612,5003,169,495495,743May 05 09:00 PM
McMinn RachelChief Strategy OfficerMay 01Sale255.12503128,3274,420Jul 17 09:00 PM
WILLIAMS NICOLEDirectorApr 20Option Exercise9.829749,5671,936Apr 22 09:00 PM
WILLIAMS NICOLEDirectorApr 20Sale278.50974271,259962Apr 22 09:00 PM
VEITINGER KLAUS R DRDirectorApr 10Option Exercise21.503918,4072,557Apr 14 09:00 PM
VEITINGER KLAUS R DRDirectorApr 10Sale272.10391106,3912,166Apr 14 09:00 PM
Pruzanski MarkCEO & PresidentApr 02Sale277.7015743,599495,743Apr 03 09:00 PM
Duncan Barbara GayleChief Financial OfficerApr 02Sale277.703910,83017,523Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 02Sale277.70843234,10219,293Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 01Option Exercise8.822,33420,58022,752Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 01Sale274.462,616718,00020,136Apr 03 09:01 PM
Duncan Barbara GayleChief Financial OfficerMar 27Sale289.821,000289,81716,264Apr 01 10:00 AM
SILVERSTEIN JONATHANDirectorMar 26Sale286.75157,20045,076,4421,120,324Mar 30 03:59 PM
ORBIMED ADVISORS LLCDirectorMar 26Sale286.75157,20045,076,4421,120,324Mar 30 03:58 PM
ORBIMED ADVISORS LLCDirectorMar 25Sale270.232,800756,6441,277,524Mar 25 07:28 PM
SILVERSTEIN JONATHANDirectorMar 25Sale270.232,800756,6441,277,524Mar 25 07:34 PM
SILVERSTEIN JONATHANDirectorMar 24Sale272.0045,60012,402,9951,280,324Mar 25 07:34 PM
ORBIMED ADVISORS LLCDirectorMar 24Sale272.0045,60012,402,9951,280,324Mar 25 07:28 PM
ORBIMED ADVISORS LLCDirectorMar 23Sale275.18159,40043,863,0671,325,924Mar 25 07:28 PM
SILVERSTEIN JONATHANDirectorMar 23Sale275.18159,40043,863,0671,325,924Mar 25 07:34 PM
WILLIAMS NICOLEDirectorMar 20Option Exercise9.829739,5571,935Mar 24 09:00 PM
WILLIAMS NICOLEDirectorMar 20Sale305.36973297,115962Mar 24 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 16Option Exercise10.403,50036,40022,296Mar 18 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 16Sale286.903,5001,004,14018,796Mar 18 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 12Option Exercise8.675,00043,33423,796Mar 16 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 12Sale285.995,0001,429,93818,796Mar 16 09:00 PM
VEITINGER KLAUS R DRDirectorMar 10Option Exercise21.503918,4072,557Mar 12 09:00 PM
VEITINGER KLAUS R DRDirectorMar 10Sale262.06391102,4652,166Mar 12 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 24Option Exercise21.5063213,5882,798Feb 26 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 24Sale222.50632140,6202,166Feb 26 09:00 PM
WILLIAMS NICOLEDirectorFeb 20Option Exercise9.829749,5671,936Feb 24 09:00 PM
WILLIAMS NICOLEDirectorFeb 20Sale216.00974210,384962Feb 24 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentFeb 17Option Exercise9.368,79482,28223,442Feb 19 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentFeb 17Sale209.414,646972,92118,796Feb 19 09:02 PM
VEITINGER KLAUS R DRDirectorFeb 10Option Exercise21.502335,0102,399Feb 12 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 10Sale195.5223345,5562,166Feb 12 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 30Option Exercise9.487,50071,06722,148Feb 03 09:00 PM
Regan Daniel PaulChief Commercial OfficerJan 30Option Exercise37.699,847371,13311,111Feb 03 09:01 PM
Regan Daniel PaulChief Commercial OfficerJan 30Sale201.079,8471,979,9631,264Feb 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentJan 30Sale205.847,5001,543,83214,648Feb 03 09:00 PM
WILLIAMS NICOLEDirectorJan 20Option Exercise9.829739,5572,438Jan 22 09:00 PM
WILLIAMS NICOLEDirectorJan 20Sale151.32973147,2341,465Jan 22 09:00 PM
VEITINGER KLAUS R DRDirectorJan 12Option Exercise21.502335,0102,399Jan 14 09:00 PM
VEITINGER KLAUS R DRDirectorJan 12Sale150.0123334,9522,166Jan 14 09:00 PM
Duncan Barbara GayleChief Financial OfficerJan 05Sale176.4914124,88417,264Jan 07 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 05Sale172.63664114,62714,648Jan 07 09:01 PM
Pruzanski MarkCEO & PresidentJan 05Sale176.4946181,360491,032Jan 07 09:02 PM
Regan Daniel PaulChief Commercial OfficerJan 05Sale176.4914625,7671,264Jan 07 09:03 PM
Duncan Barbara GayleChief Financial OfficerJan 02Option Exercise31.901,00031,90018,405Jan 05 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 02Sale158.7137659,67515,312Jan 05 09:01 PM
Duncan Barbara GayleChief Financial OfficerJan 02Sale156.401,000156,40017,405Jan 05 09:00 PM
Benatti LucaDirectorDec 15Buy139.86800111,8881,292Dec 15 09:00 PM
VEITINGER KLAUS R DRDirectorDec 10Option Exercise21.502335,0102,399Dec 12 09:00 PM
VEITINGER KLAUS R DRDirectorDec 10Sale144.1623333,5892,166Dec 12 09:00 PM
Pruzanski MarkCEO & PresidentNov 19Option Exercise8.736,71658,603486,625Nov 20 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentNov 17Option Exercise10.404,00041,60018,855Nov 19 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentNov 17Sale158.824,790760,73014,065Nov 19 09:00 PM
AKKARAJU SRINIVASDirectorNov 12Buy167.192,000334,3877,642Nov 13 09:32 AM
AKKARAJU SRINIVASDirectorNov 11Option Exercise21.502,50053,7505,642Nov 13 09:32 AM
VEITINGER KLAUS R DRDirectorNov 10Option Exercise21.502335,0102,399Nov 12 09:00 PM